Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis.
Alberto MiglioreGiuseppe PompilioDavide IntegliaJoe ZhuoEvo AlemaoPublished in: Therapeutic advances in musculoskeletal disease (2021)
Assessment of the effectiveness of different drug treatment strategies in patients with rheumatoid arthritis: an analysis of the published literature Rheumatoid arthritis (RA) is a chronic disease in which inflammation affects joints along with the entire body; this may cause significant pain, joint damage, physical disability, a decreased quality of life, and an increased risk of death.Tumor necrosis factor inhibitors (TNFis) are a common choice as first-line drugs to treat RA. Although they are effective in many patients, therapy with a TNFi is not successful within the first year of treatment in approximately one-third of patients due to either a lack of efficacy or safety issues.When TNFi therapy is unsuccessful, the options are to "cycle" to another TNFi or to "switch" to another drug with a different mechanism of action (MOA). Further studies are needed to help doctors decide the best treatment strategy for their patients when treatment with an initial TNFi fails.This study analyzed 25 published studies in which patients were either "cycled" to another TNFi or "switched" to a drug with a different MOA after unsuccessful treatment with an initial TNFi.The results showed that "switching" to a drug with a different MOA was a better treatment strategy than "cycling" to another TNFi; "switching" increased the chance of clinically meaningful improvement in disease status and lowered the chance of having to stop treatment for any reason.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- systematic review
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- oxidative stress
- peritoneal dialysis
- multiple sclerosis
- disease activity
- spinal cord
- mesenchymal stem cells
- stem cells
- mental health
- cell therapy
- pain management
- physical activity
- adverse drug
- high intensity
- idiopathic pulmonary fibrosis
- neuropathic pain
- smoking cessation